Trial Profile
Pilot Study Of Long-Acting Octreotide (Octreotide LAR Depot) In The Treatment Of Patients With Severe Polycystic Liver Disease
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Sep 2015
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Polycystic liver disease
- Focus Therapeutic Use
- 09 Jul 2015 Results published in the Mayo Clinic Proceedings.
- 04 May 2014 New trial record